Make informed decisions. Try the FT.
Add this topic to your myFT Digest for news straight to your inbox
Prognosis is for further financial pain for chronic GlaxoSmithKline shareholders
The company is committed to pharma but that looks expensive
Anglo-Dutch group’s acquisition of malted beverages is a bet on India growth
Shares lose 7 per cent on news of drugmaker’s first big acquisition under Emma Walmsley
Anglo-Dutch consumer company beats out rival bid from Nestlé for $4bn nutrition business
UK drugmaker tightens full-year guidance towards upper end of expectations
Competition rises to secure GlaxoSmithKline’s prized malted drink brand
Prevention trial aims to prove to cash strapped service that products are value for money
A niche drink in India would not come cheap for bidders
Monthly injections to replace daily treatment as health group seeks to boost market share
Iain Mackay joinspharmaceuticals group from HSBC
As earnings season kicks off, look for dividend winners at home and abroad
Amazon results; Qualcomm, UBS, Ryanair and GSK also in the news
Clarity on strategy is not among the benefits promised by drug discovery tie-up
Equity stake in Google Ventures-backed group comes as drugmaker unveils ‘major restructuring’
I crashed at 230mph, had three months in hospital and was back racing a year later
It makes no sense to rush a sale of consumer unit before pharma business strengthens
Drugmaker focuses on R&D as chairman mulls consumer health demerger
Chairman weighs spinning off consumer division after pressure from investors
The legal backlash against drugmakers echoes the fight against Big Tobacco
UK pharma company removed work history at Purdue from Lewent’s biography
Domestic biotech lures executives with promise of freer hand, more pay and equity
